These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 12842427

  • 1. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
    Bowman JE, Reese JS, Lingas KT, Gerson SL.
    Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
    [Abstract] [Full Text] [Related]

  • 2. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients.
    Davis BM, Reese JS, Lingas K, Gerson SL.
    J Hematother Stem Cell Res; 2003 Aug; 12(4):375-87. PubMed ID: 12965075
    [Abstract] [Full Text] [Related]

  • 3. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S, Seshadri R, Pegg AE, Williams DA.
    Cancer Res; 2000 Sep 15; 60(18):5187-95. PubMed ID: 11016647
    [Abstract] [Full Text] [Related]

  • 4. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
    Lee K, Gerson SL, Maitra B, Koç ON.
    J Hematother Stem Cell Res; 2001 Oct 15; 10(5):691-701. PubMed ID: 11672516
    [Abstract] [Full Text] [Related]

  • 5. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM, Reese JS, Koç ON, Lee K, Schupp JE, Gerson SL.
    Cancer Res; 1997 Nov 15; 57(22):5093-9. PubMed ID: 9371508
    [Abstract] [Full Text] [Related]

  • 6. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL.
    Hum Gene Ther; 1999 Nov 20; 10(17):2769-78. PubMed ID: 10584923
    [Abstract] [Full Text] [Related]

  • 7. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
    Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL.
    J Clin Invest; 2003 Nov 20; 112(10):1561-70. PubMed ID: 14617757
    [Abstract] [Full Text] [Related]

  • 8. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON, Reese JS, Davis BM, Liu L, Majczenko KJ, Gerson SL.
    Hum Gene Ther; 1999 Apr 10; 10(6):1021-30. PubMed ID: 10223735
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
    Kramer BA, Lemckert FA, Alexander IE, Gunning PW, McCowage GB.
    J Gene Med; 2006 Sep 10; 8(9):1071-85. PubMed ID: 16927363
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
    Jansen M, Sorg UR, Ragg S, Flasshove M, Seeber S, Williams DA, Moritz T.
    Cancer Gene Ther; 2002 Sep 10; 9(9):737-46. PubMed ID: 12189523
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
    Larochelle A, Choi U, Shou Y, Naumann N, Loktionova NA, Clevenger JR, Krouse A, Metzger M, Donahue RE, Kang E, Stewart C, Persons D, Malech HL, Dunbar CE, Sorrentino BP.
    J Clin Invest; 2009 Jul 10; 119(7):1952-63. PubMed ID: 19509470
    [Abstract] [Full Text] [Related]

  • 16. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
    Woolford LB, Southgate TD, Margison GP, Milsom MD, Fairbairn LJ.
    J Gene Med; 2006 Jan 10; 8(1):29-34. PubMed ID: 16075413
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
    Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP.
    Mol Ther; 2001 Jan 10; 3(1):78-87. PubMed ID: 11162314
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
    Reese JS, Davis BM, Liu L, Gerson SL.
    Clin Cancer Res; 1999 Jan 10; 5(1):163-9. PubMed ID: 9918215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.